Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 918633-87-1 Chemical Structure| 918633-87-1

Structure of Evofosfamide
CAS No.: 918633-87-1

Chemical Structure| 918633-87-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TH-302 is selective hypoxia-activated prodrug targeting hypoxic regions of solid tumors with IC50 of 19 nM, demonstrates 270-fold enhanced cytotoxicity under hypoxia versus their potency under aerobic conditions, stable to cytochrome P450 metabolism.

Synonyms: TH302; TH-302

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Evofosfamide

CAS No. :918633-87-1
Formula : C9H16Br2N5O4P
M.W : 449.04
SMILES Code : O=P(NCCBr)(NCCBr)OCC1=CN=C([N+]([O-])=O)N1C
Synonyms :
TH302; TH-302
MDL No. :MFCD22420822
InChI Key :UGJWRPJDTDGERK-UHFFFAOYSA-N
Pubchem ID :11984561

Safety of Evofosfamide

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H315-H317-H319-H335-H360
Precautionary Statements:P201-P261-P280-P305+P351+P338-P308+P313
Class:6.1
UN#:2811
Packing Group:

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HNE-1 0.31 ± 0.07 μmol/L 24 hours Evaluate the cytotoxicity of Evofosfamide under hypoxic conditions, showing an IC50 of 0.31 ± 0.07 μmol/L in HNE-1 cells with hypoxia selectivity over 300-fold Cancer Commun (Lond). 2018 May 3;38(1):15
HONE-1 7.62 ± 0.67 μmol/L 24 hours Evaluate the cytotoxicity of Evofosfamide under hypoxic conditions, showing an IC50 of 7.62 ± 0.67 μmol/L in HONE-1 cells Cancer Commun (Lond). 2018 May 3;38(1):15
CNE-2 8.33 ± 0.75 μmol/L 24 hours Evaluate the cytotoxicity of Evofosfamide under hypoxic conditions, showing an IC50 of 8.33 ± 0.75 μmol/L in CNE-2 cells Cancer Commun (Lond). 2018 May 3;38(1):15
Nalm-6 5, 7.5, 10, or 15 μM 6 hours Evaluate cytotoxicity of TH-302 under different oxygen conditions Clin Cancer Res. 2016 Apr 1;22(7):1687-98
REH 5, 7.5, 10, or 15 μM 6 hours Evaluate cytotoxicity of TH-302 under different oxygen conditions Clin Cancer Res. 2016 Apr 1;22(7):1687-98
MOLM-13 5, 7.5, 10, or 15 μM 6 hours Evaluate cytotoxicity of TH-302 under different oxygen conditions Clin Cancer Res. 2016 Apr 1;22(7):1687-98
OCI-AML3 5, 7.5, 10, or 15 μM 6 hours Evaluate cytotoxicity of TH-302 under different oxygen conditions Clin Cancer Res. 2016 Apr 1;22(7):1687-98
KG-1 5, 7.5, 10, or 15 μM 6 hours Evaluate cytotoxicity of TH-302 under different oxygen conditions Clin Cancer Res. 2016 Apr 1;22(7):1687-98
KBM-5 5, 7.5, 10, or 15 μM 6 hours Evaluate cytotoxicity of TH-302 under different oxygen conditions Clin Cancer Res. 2016 Apr 1;22(7):1687-98

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice PC3 xenograft models Intraperitoneal injection 75 mg/kg Once per week for 28 days TH-302 significantly inhibited NEPC tumor growth Nat Commun. 2019 Jan 17;10(1):278
Mice TRAMP-C2 prostate tumor model Intraperitoneal injection 50 mg/kg Once daily for 5 consecutive days, 2 cycles The combination of TH-302 with αCTLA-4/αPD-1 significantly improved the cure rate of TRAMP-C2 prostate tumors (82% overall survival), superior to TH-302 alone (30% overall survival) or dual antibody therapy (55% overall survival). J Clin Invest. 2018 Nov 1;128(11):5137-5149
NOD/Scid/IL2R γ-KO mice AML xenograft model Intraperitoneal injection 50 mg/kg 3 times a week for 3 weeks Evaluate anti-leukemia activity of TH-302 in AML models Clin Cancer Res. 2016 Apr 1;22(7):1687-98
Female athymic nude mice Human pancreatic ductal adenocarcinoma (PDAC) xenograft models Intraperitoneal injection 80 mg/kg Daily for 5 days Evaluate the therapeutic effect of TH-302 on three PDAC tumors. Results showed TH-302 was most effective in hypoxic Hs766t tumors (25.0±7.7 days increase in survival time) and least effective in less hypoxic Su.86.86 tumors (0.7±0.6 days increase in survival time). Cancer Res. 2018 Jul 15;78(14):3783-3792
NSG mice Bone lesion model Intraperitoneal injection 20 mg/kg Every 2 days for 2 weeks Evaluate the therapeutic effect of TH-302 on myeloma bone lesions, results showed TH-302 significantly alleviated bone destruction Oncogene. 2021 Feb;40(7):1231-1241
NOD/SCID mice HCC xenograft model Intravenous injection 50 mg/kg Once weekly for seven times To evaluate the antitumor effect of Evofosfamide combined with HAP103 Ab in HCC xenograft models. Results showed that the combination therapy significantly inhibited tumor growth with minimal side effects. Int J Biol Sci. 2024 Feb 11;20(5):1634-1651
New Zealand white rabbits VX2 tumor model Intraarterial injection 7.7 mg/kg Single dose, observed for 14 days To evaluate the safety and anticancer efficacy of Evofosfamide in liver cancer. Results showed that the cTACE+Evo group demonstrated smaller tumor volumes, lower tumor growth rates, and higher necrotic fractions compared to cTACE. cTACE+Evo also significantly reduced the hypoxic fraction and hypoxic compartment. Clin Cancer Res. 2017 Jan 15;23(2):536-548
BALB/c nude mice HNE-1 NPC xenograft model Intraperitoneal injection 50 or 75 mg/kg Twice a week for 2 weeks Evaluate the antitumor activity of Evofosfamide as a single agent or in combination with DDP, showing TGI values of 43% and 55% for 50 and 75 mg/kg Evofosfamide monotherapy, and 49% and 71% when combined with DDP Cancer Commun (Lond). 2018 May 3;38(1):15
C57BL/6 mice MC38 colorectal cancer and E0771 triple negative breast cancer (TNBC) models Intraperitoneal injection 50 mg/kg Days 6 to 10 following tumor inoculation To evaluate the effect of Evofosfamide in immunotherapy non-responsive tumors, results showed that Evofosfamide combined with immunotherapy significantly reduced tumor hypoxia and improved therapeutic outcomes. Clin Cancer Res. 2022 Jan 15;28(2):327-337

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.23mL

0.45mL

0.22mL

11.13mL

2.23mL

1.11mL

22.27mL

4.45mL

2.23mL

 

Historical Records

Categories